Cure My Disease

Don't miss your cure!

 Log in / Sign up

New BCG vaccine could be just as good for bladder cancer

NCT ID NCT05037279

Recruiting now Disease control Sponsor: Verity Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing a new version of the BCG vaccine, called Verity-BCG, against the standard BCG treatment (OncoTICE) in 540 people with intermediate or high-risk non-muscle invasive bladder cancer who have not received BCG before. The goal is to see if Verity-BCG is at least as effective at preventing cancer recurrence over 24 months. Participants will receive either Verity-BCG or OncoTICE through a catheter into the bladder, followed by maintenance doses for up to 3 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Bacillus Calmette-Guerin (BCG) vaccine
What this could lead to
If it works, this could offer a new, equally effective BCG option for bladder cancer patients, potentially improving drug supply and access.
What could go wrong
This is a non-inferiority trial, meaning it only aims to show Verity-BCG is not worse than the current standard. Even if successful, it may not be better. The trial is still recruiting, so results are years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma non-invasive bladder urothelial carcinoma Recurrence urinary bladder cancer urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER BLADDER CANCER RECURRENT NEOPLASM RECURRENCE NON-INVASIVE BLADDER UROTHELIAL CARCINOMA UROTHELIAL CARCINOMA BLADDER UROTHELIAL CARCINOMA RECURRENT

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Site 01

    RECRUITING

    Toronto, Ontario, Canada

  • Site 02

    NOT_YET_RECRUITING

    Toronto, Ontario, Canada

  • Site 04

    RECRUITING

    Kingston, Ontario, Canada

  • Site 05

    RECRUITING

    Vancouver, British Columbia, Canada

  • Site 08

    RECRUITING

    Toronto, Ontario, Canada

  • Site 10

    NOT_YET_RECRUITING

    Montreal, Quebec, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.